Cohance Lifesciences Ltd.

NSE: COHANCE | BSE: 543064 | ISIN: INE03QK01018 | Industry: Pharmaceuticals
| Expensive Performer

996.40
0.66%
Geojit BNP Paribas
During the year total revenues grew by 27% to Rs.834crs driven by 18% growth in CRAMS, 41% growth in Speciality chemicals and 40% growth in Formulations. In the CRAMS segment, the company has been able to add new customers during the year and the segment is now 56% of total revenues. In the coming year, the management stated that new projects may be difficult to undertake owing to the ongoing Covid-19 scenario. In CRAMS, the company plans to integrate into APIs and later into formulations, in addition to intermediates, which it is currently focusing on. We expect a revenue CAGR of 13% for CRAMS over FY20-FY22E...
Cohance Lifesciences Ltd. is trading below its 100 day SMA of 1018.8
More from Cohance Lifescien…
All earning calls
Investor presentations from Cohance Lifescien…
All investor presentations